Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Other financing activities (2016 - 2024)

Mimedx (MDXG) has disclosed Other financing activities for 7 consecutive years, with -$1.2 million as the latest value for Q4 2024.

  • Quarterly Other financing activities fell 2126.92% to -$1.2 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$1.2 million through Sep 2025, down 210.39% year-over-year, with the annual reading at -$57000.0 for FY2024, 9.62% down from the prior year.
  • Other financing activities hit -$1.2 million in Q4 2024 for Mimedx, down from $1.1 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $4.7 million in Q4 2020 to a low of -$1.2 million in Q4 2024.
  • Historically, Other financing activities has averaged $1.5 million across 3 years, with a median of $1.1 million in 2024.
  • Biggest five-year swings in Other financing activities: surged 145.64% in 2020 and later plummeted 2126.92% in 2024.
  • Year by year, Other financing activities stood at $4.7 million in 2020, then tumbled by 101.11% to -$52000.0 in 2023, then tumbled by 2126.92% to -$1.2 million in 2024.
  • Business Quant data shows Other financing activities for MDXG at -$1.2 million in Q4 2024, $1.1 million in Q1 2024, and -$52000.0 in Q4 2023.